A detailed history of Bank Of America Corp transactions in Immunovant, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 243,334 shares of IMVT stock, worth $6.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
243,334
Previous 208,630 16.63%
Holding current value
$6.69 Million
Previous $6.74 Million 4.69%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $871,070 - $1.1 Million
34,704 Added 16.63%
243,334 $6.42 Million
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $416,091 - $601,937
-13,746 Reduced 6.18%
208,630 $6.74 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $1.43 Million - $2.01 Million
45,516 Added 25.74%
222,376 $9.37 Million
Q2 2023

Aug 14, 2023

SELL
$14.2 - $23.75 $3.31 Million - $5.53 Million
-232,954 Reduced 56.84%
176,860 $3.36 Million
Q1 2023

May 12, 2023

BUY
$15.27 - $19.72 $2.67 Million - $3.45 Million
175,011 Added 74.54%
409,814 $6.36 Million
Q4 2022

Feb 10, 2023

BUY
$6.59 - $17.75 $1.38 Million - $3.72 Million
209,331 Added 821.81%
234,803 $4.17 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $43,418 - $70,375
11,048 Added 76.59%
25,472 $142,000
Q2 2022

Aug 12, 2022

SELL
$3.38 - $5.65 $39,691 - $66,347
-11,743 Reduced 44.88%
14,424 $56,000
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $1.01 Million - $1.75 Million
-199,281 Reduced 88.39%
26,167 $144,000
Q4 2021

Feb 08, 2022

BUY
$7.33 - $9.32 $953,940 - $1.21 Million
130,142 Added 136.55%
225,448 $1.92 Million
Q3 2021

Nov 15, 2021

SELL
$7.01 - $11.37 $276,299 - $448,148
-39,415 Reduced 29.26%
95,306 $828,000
Q2 2021

Sep 13, 2021

BUY
$9.4 - $16.85 $1.27 Million - $2.27 Million
134,721 New
134,721 $1.43 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.